Drug Search Results
More Filters [+]

AGN-201781

Alternative Names: agn-201781, agn201781, agn 201781
Latest Update: 2016-02-24
Latest Update Note: Clinical Trial Update

Product Description

Allergan was developing agn-201781, an oral drug, for the treatment of postherpetic neuralgia or post-traumatic peripheral neuralgia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00533351)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AGN-201781

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Neuralgia, Postherpetic|Neuralgia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2007-003787-21

P2

Terminated

Neuralgia, Postherpetic

2008-06-20

NCT00533351

P2

Terminated

Neuralgia

2008-06-01

Recent News Events

Date

Type

Title